Halberd Corp
OTC:HALB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Halberd Corp
PP&E Net
Halberd Corp
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halberd Corp
OTC:HALB
|
PP&E Net
$1.6m
|
CAGR 3-Years
194%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$7.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
PP&E Net
$708.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
38%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
PP&E Net
$165.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
PP&E Net
$1.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
PP&E Net
$2.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Halberd Corp
Glance View
Halberd Corp. is a development stage company, researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. The company is headquartered in Jackson Center, Pennsylvania. The company went IPO on 2009-06-12. The firm is a research-based company that intends to discover and develop medical treatments for a range of diseases. The firm's extracorporeal treatment is applicable for hard-to-cure blood-borne and neurologic diseases, such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. The company is also developing treatment for coronavirus disease of 2019 (Covid-19), obesity, such as high blood pressure, diabetes, heart disease, stroke, and cancer.
See Also
What is Halberd Corp's PP&E Net?
PP&E Net
1.6m
USD
Based on the financial report for Jul 31, 2012, Halberd Corp's PP&E Net amounts to 1.6m USD.
What is Halberd Corp's PP&E Net growth rate?
PP&E Net CAGR 3Y
194%
Over the last year, the PP&E Net growth was 135 642%. The average annual PP&E Net growth rates for Halberd Corp have been 194% over the past three years .
